Evolus, Inc. (EOLS) News
Filter EOLS News Items
EOLS News Results
|Loading, please wait...|
EOLS News Highlights
- EOLS's 30 day story count now stands at 3.
- Over the past 2 days, the trend for EOLS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest EOLS News From Around the Web
Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Evolus ( NASDAQ:EOLS ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.9m (up 27% from 3Q 2021). Net...
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
NEWPORT BEACH, Calif., November 08, 2022--Evolus reports financial results for the third quarter ended September 30, 2022 and provides a business update.
NEWPORT BEACH, Calif., November 02, 2022--Evolus announces that members of its management team will be participating in two investment conferences in November.
NEWPORT BEACH, Calif., October 25, 2022--Evolus announces that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022.
NEWPORT BEACH, Calif., October 04, 2022--Evolus, Inc., launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva®▼(botulinum toxin type A) last month.
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
NEWPORT BEACH, Calif., September 21, 2022--Evolus celebrates the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims.
In this article, we will discuss the 13 stocks to sell now according to billionaire Larry Robbins. If you want to skip the detailed analysis of Robbins’ investment philosophy, go directly to 5 Stocks to Sell Now According to Billionaire Larry Robbins. American investor and philanthropist Larry Robbins was born in 1969. Glenview Capital Management, […]
Evolus, Inc. is small-cap company rapidly taking market share in the growing "aesthetic neurotoxin" space -- a.k.a. Using the April $10 call strikes, fashion a covered call order with a net debit in the $7.60 to $7.80 a share range (net stock price - option premium).
For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .